- Home
- AIRT vs MGX Comparison
AIRT vs MGX Comparison
Compare AIRT & MGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRT
- MGX
- Stock Information
- Founded
- AIRT 1980
- MGX 2018
- Country
- AIRT United States
- MGX United States
- Employees
- AIRT N/A
- MGX N/A
- Industry
- AIRT Air Freight/Delivery Services
- MGX
- Sector
- AIRT Consumer Discretionary
- MGX
- Exchange
- AIRT Nasdaq
- MGX NYSE
- Market Cap
- AIRT 53.2M
- MGX 62.1M
- IPO Year
- AIRT N/A
- MGX 2024
- Fundamental
- Price
- AIRT $21.13
- MGX $1.64
- Analyst Decision
- AIRT
- MGX Strong Buy
- Analyst Count
- AIRT 0
- MGX 4
- Target Price
- AIRT N/A
- MGX $13.00
- AVG Volume (30 Days)
- AIRT 2.7K
- MGX 682.1K
- Earning Date
- AIRT 06-27-2025
- MGX 08-13-2025
- Dividend Yield
- AIRT N/A
- MGX N/A
- EPS Growth
- AIRT N/A
- MGX N/A
- EPS
- AIRT N/A
- MGX N/A
- Revenue
- AIRT $291,850,000.00
- MGX $45,263,000.00
- Revenue This Year
- AIRT N/A
- MGX N/A
- Revenue Next Year
- AIRT N/A
- MGX $11.75
- P/E Ratio
- AIRT N/A
- MGX N/A
- Revenue Growth
- AIRT 1.75
- MGX N/A
- 52 Week Low
- AIRT $14.56
- MGX $1.23
- 52 Week High
- AIRT $30.60
- MGX $5.50
- Technical
- Relative Strength Index (RSI)
- AIRT 54.46
- MGX 56.10
- Support Level
- AIRT $18.86
- MGX $1.45
- Resistance Level
- AIRT $22.50
- MGX $1.70
- Average True Range (ATR)
- AIRT 1.01
- MGX 0.12
- MACD
- AIRT -0.09
- MGX 0.02
- Stochastic Oscillator
- AIRT 42.31
- MGX 82.13
About AIRT Air T Inc.
Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.
About MGX METAGENOMI INC
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.